Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

Replacing bleomycin with brentuximab vedotin in standard ABVD therapy led to a “modest improvement” in outcomes for patients with Hodgkin lymphoma, without increased long-term toxicity. Dr. Connors shares results from the ECHELON 1 trial, which were presented as a plenary abstract at the 2017 ASH Annual Meeting.

SHARE